Moderna Files 8-K: Financials & Reg FD Update

Ticker: MRNA · Form: 8-K · Filed: 2024-09-12T00:00:00.000Z

Sentiment: neutral

Topics: financial-statements, regulation-fd, filing-update

Related Tickers: MRNA

TL;DR

Moderna filed an 8-K today for routine financial and Reg FD updates. No major news.

AI Summary

On September 12, 2024, Moderna, Inc. filed an 8-K report to disclose information regarding financial statements and exhibits, as well as a Regulation FD disclosure. The filing does not contain specific financial figures or new material events beyond routine disclosures.

Why It Matters

This 8-K filing serves as a routine update for investors, providing access to financial statements and ensuring compliance with Regulation FD disclosure requirements.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and Regulation FD disclosure, indicating no new material events or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Moderna, Inc.?

The primary purpose of this 8-K filing is to disclose information regarding financial statements and exhibits, and to provide a Regulation FD disclosure.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is September 12, 2024.

What is Moderna, Inc.'s principal executive office address?

Moderna, Inc.'s principal executive office is located at 325 Binney Street, Cambridge, MA 02142.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

What was Moderna's former company name?

Moderna's former company name was Moderna Therapeutics, Inc.

From the Filing

0001682852-24-000049.txt : 20240912 0001682852-24-000049.hdr.sgml : 20240912 20240912060314 ACCESSION NUMBER: 0001682852-24-000049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240912 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240912 DATE AS OF CHANGE: 20240912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 241293810 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 8-K 1 mrna-20240912.htm 8-K mrna-20240912 0001682852 false 0001682852 2024-09-12 2024-09-12   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware   001-38753   81-3467528  (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.)   325 Binney Street Cambridge , MA   02142 (Address of principal executive offices)   (Zip code) Registrant’s telephone number, including area code: ( 617 )  714-6500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company       ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐ Item 7.01    Regulation FD Disclosure. On September 12, 2024, Moderna, Inc. (the “Company”) issued a press release providing research and development and business updates in connection with the Company’s investor event on the same date. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed in

View on Read The Filing